- Home
- GITS vs APVO Comparison
GITS vs APVO Comparison
Compare GITS & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- APVO
- Stock Information
- Founded
- GITS 2018
- APVO 2016
- Country
- GITS South Korea
- APVO United States
- Employees
- GITS N/A
- APVO N/A
- Industry
- GITS
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- GITS
- APVO Health Care
- Exchange
- GITS Nasdaq
- APVO Nasdaq
- Market Cap
- GITS 4.1M
- APVO 4.1M
- IPO Year
- GITS N/A
- APVO N/A
- Fundamental
- Price
- GITS $2.18
- APVO $1.64
- Analyst Decision
- GITS
- APVO Strong Buy
- Analyst Count
- GITS 0
- APVO 1
- Target Price
- GITS N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- GITS 27.5K
- APVO 153.4K
- Earning Date
- GITS 08-15-2025
- APVO 08-11-2025
- Dividend Yield
- GITS N/A
- APVO N/A
- EPS Growth
- GITS N/A
- APVO N/A
- EPS
- GITS N/A
- APVO N/A
- Revenue
- GITS $29.00
- APVO N/A
- Revenue This Year
- GITS N/A
- APVO N/A
- Revenue Next Year
- GITS N/A
- APVO N/A
- P/E Ratio
- GITS N/A
- APVO N/A
- Revenue Growth
- GITS N/A
- APVO N/A
- 52 Week Low
- GITS $0.87
- APVO $1.61
- 52 Week High
- GITS $9.78
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- GITS 46.10
- APVO 25.93
- Support Level
- GITS $2.12
- APVO $1.87
- Resistance Level
- GITS $2.34
- APVO $2.07
- Average True Range (ATR)
- GITS 0.16
- APVO 0.17
- MACD
- GITS -0.00
- APVO 0.02
- Stochastic Oscillator
- GITS 35.00
- APVO 4.04
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.